Prelude Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.28M | Sell |
50,635
-100
| -0.2% | -$2.36K | 0.09% | 246 |
|
|
2026
Q1 | $1.15M | Buy |
50,735
+6,740
| +15% | +$150K | 0.09% | 274 |
|
|
2025
Q4 | $1.14M | Buy |
43,995
+7,460
| +20% | +$177K | 0.08% | 268 |
|
|
2025
Q3 | $942K | Buy |
36,535
+12,300
| +51% | +$302K | 0.07% | 317 |
|
|
2025
Q2 | $579K | Sell |
24,235
-104
| -0.4% | -$2.62K | 0.06% | 395 |
|
|
2025
Q1 | $605K | Buy |
24,339
+4,804
| +25% | +$115K | 0.05% | 448 |
|
|
2024
Q4 | $368K | Sell |
19,535
-2,400
| -11% | -$42.1K | 0.02% | 714 |
|
|
2024
Q3 | $330K | Buy |
21,935
+2,518
| +13% | +$43K | 0.02% | 814 |
|
|
2024
Q2 | $556K | Buy |
19,417
+4,892
| +34% | +$139K | 0.04% | 498 |
|
|
2024
Q1 | $424K | Buy |
14,525
+7,841
| +117% | +$241K | 0.02% | 705 |
|
|
2023
Q4 | $226K | Buy |
+6,684
| New | +$196K | 0.01% | 887 |
|
|
2023
Q3 | – | Sell |
-6,990
| Closed | -$280K | – | 1297 |
|
|
2023
Q2 | $280K | Buy |
+6,990
| New | +$289K | 0.02% | 680 |
|
|
2022
Q3 | – | Sell |
-9,837
| Closed | -$573K | – | 1837 |
|
|
2022
Q2 | $573K | Buy |
9,837
+2,491
| +34% | +$163K | 0.02% | 744 |
|
|
2022
Q1 | $561K | Sell |
7,346
-4,481
| -38% | -$299K | 0.02% | 813 |
|
|
2021
Q4 | $712K | Buy |
+11,827
| New | +$652K | 0.02% | 807 |
|
|
2020
Q3 | – | Sell |
-15,447
| Closed | -$811K | – | 2217 |
|
|
2020
Q2 | $811K | Buy |
15,447
+3,058
| +25% | +$128K | 0.04% | 357 |
|
|
2020
Q1 | $415K | Buy |
12,389
+6,875
| +125% | +$286K | 0.03% | 341 |
|
|
2019
Q4 | $250K | Sell |
5,514
-3,160
| -36% | -$134K | 0.01% | 785 |
|
|
2019
Q3 | $330K | Sell |
8,674
-8,653
| -50% | -$345K | 0.01% | 635 |
|
|
2019
Q2 | $754K | Buy |
17,327
+17,121
| +8,311% | +$727K | 0.04% | 414 |
|
|
2019
Q1 | $8K | Buy |
+206
| New | +$8.04K | ﹤0.01% | 1537 |
|
|
2016
Q3 | – | Sell |
-1,144
| Closed | -$44.8K | – | 1757 |
|
|
2016
Q2 | $39K | Sell |
1,144
-950
| -45% | -$46.7K | 0.01% | 1092 |
|
|
2016
Q1 | $111K | Sell |
2,094
-1,239
| -37% | -$72.5K | 0.02% | 726 |
|
|
2015
Q4 | $256K | Buy |
+3,333
| New | +$189K | 0.04% | 461 |
|
|
2015
Q1 | – | Sell |
-300
| Closed | -$27K | – | 2109 |
|
|
2014
Q4 | $27K | Sell |
300
-950
| -76% | -$89.9K | ﹤0.01% | 1655 |
|
|
2014
Q3 | $121K | Buy |
1,250
+1,150
| +1,150% | +$112K | 0.02% | 1002 |
|
|
2014
Q2 | $9K | Buy |
+100
| New | +$7.62K | ﹤0.01% | 1823 |
|
Other funds holding PCRX
DPCM
Prelude Capital Management's PCRX Position: Q2 2026 in Review
Prelude Capital Management reduced its Pacira BioSciences (PCRX) stake by 0.2% in Q2 2026, selling an estimated $2.36K and leaving 50,635 shares worth $1.28M. The position accounts for 0.09% of the portfolio, ranked #246.
Prelude Capital Management first reported a position in PCRX in Q2 2014 and has held it in 27 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- Prelude Capital Management held 50,635 shares of Pacira BioSciences worth $1.28M as of Q2 2026.
- Prelude Capital Management sold 100 Pacira BioSciences shares in Q2 2026, an estimated $2.36K.
- Pacira BioSciences made up 0.09% of Prelude Capital Management's portfolio in Q2 2026, its #246 holding.
- Prelude Capital Management first reported a position in Pacira BioSciences in Q2 2014 and has held it in 27 quarters since.
- 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.